UTRECHT , The Netherlands, and CAMBRIDGE, Mass. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Merus N.V.  (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that Bill Lundberg , M.D., President and Chief

– Lead program Zenocutuzumab remains on track – – Dr. Andrew Joe appointed Chief Medical Officer – – Merus extends cash runway into 2H 2022 – UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S.

Dr. Joe brings seasoned research and development leadership and deep expertise in the clinical development of immuno-oncology, antibody, and targeted therapies for cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V.

Caris to provide DNA and RNA molecular testing to support  patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial UTRECHT, The Netherlands and CAMBRIDGE, Mass. and IRVING, Texas , July 13, 2020 (GLOBE NEWSWIRE) -- Merus N.V.

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that

– MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers – – MCLA-117 demonstrates limited clinical activity in Phase 1 trial – – Extensive panel of novel CD3 bispecific antibodies provides important insights and

MCLA-128, zenocutuzumab, Phase 1/2 eNRGy trial remains on track MCLA-117 program update to be presented at upcoming medical meeting Anand Mehra , M.D. to succeed Russell Greig , Ph.D. as Chairman and Paolo Pucci Nominated for Appointment to Merus Board of Directors UTRECHT, The Netherlands and

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , March 12, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics TM ), today announced financial results

— Bill Lundberg , M.D., nominated for appointment as Chief Executive Officer — — Ton Logtenberg, Ph.D., to step down after 16 years of leadership — — Transition to occur December 31, 2019 — UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Merus N.V.

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced financial results for the third

UTRECHT, The Netherlands , and CAMBRIDGE, Mass. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an underwritten public offering of 4,750,000 common shares, at a public offering price of

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics ® , today announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shares.

Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Of nine patients enrolled across the MCLA-128 Early Access Program

Company to host investor call on Monday, October 28th at 8:00AM ET UTRECHT, The Netherlands and BOSTON , Oct. 25, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage bispecific antibody company developing Biclonics®, innovative full-length

UTRECHT, The Netherlands , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the

UTRECHT, Netherlands , June 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D.,

UTRECHT, The Netherlands , May 30, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the

UTRECHT, The Netherlands , May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General

UTRECHT, Netherlands , May 20, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D.,

UTRECHT, Netherlands , May 09, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the first patient has been treated in its Phase 1 trial evaluating

Multiple Updates from Biclonics® Clinical Trials Expected in 2019 UTRECHT, The Netherlands , April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics ® , innovative full-length human

CD137 and PD-L1 bispecific antibody with context-dependent T cell activation UTRECHT, Netherlands , April 01, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human

UTRECHT, Netherlands , March 11, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D.,

UTRECHT, Netherlands, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Mark Throsby, Ph.D., Executive Vice President and Chief Scientific

MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD137 UTRECHT, The Netherlands, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today

Merus to retain all global rights outside of China Betta Pharmaceuticals to fund global IND-enabling activities UTRECHT, the Netherlands, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing

Clinical milestones for four lead Biclonics ®  programs expected in 2019 Cash expected to be sufficient to fund operations into the second quarter of 2021 UTRECHT, The Netherlands, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage

Merus and Regeneron to cross-license patents relating to certain antibody generation platform technologies Regeneron to purchase $15 million of Merus common shares UTRECHT, The Netherlands, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company

UTRECHT, The Netherlands, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., President and Chief Executive Officer of Merus, will

UTRECHT, The Netherlands, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President, Chief Business Officer and Head of

Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S. Peter B. Silverman, J.D., appointed EVP, General Counsel Jillian Connell joins as VP, Investor Relations and Corporate Communications UTRECHT, The Netherlands, Sept. 27, 2018 (GLOBE NEWSWIRE) --  Merus N.V. (Nasdaq:MRUS), a

UTRECHT, The Netherlands, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., President and Chief Executive Officer, will participate in

- Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of Bispecific Antibodies - UTRECHT, The Netherlands, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody

MCLA-128 Phase 1/2 clinical data from the gastric cancer cohort will be presented at the European Society for Medical Oncology Congress in October 2018 UTRECHT, The Netherlands, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage

UTRECHT, The Netherlands, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President and Chief Business Officer, will present

- Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors - - MCLA-128’s unique mechanism of action published in the scientific journal Cancer Cell - UTRECHT, The Netherlands, July 26, 2018 (GLOBE NEWSWIRE) --  Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “our” or

UTRECHT, The Netherlands, July 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Annual General Meeting of Shareholders will be held on Friday, July 20,

UTRECHT, The Netherlands , May 31, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced that Hui Liu , Ph.D., Executive Vice President and Chief Business Officer, will

- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands , May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been

UTRECHT, The Netherlands , May 15, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the unique mechanism of action (MOA) of MCLA-128, the Company’s most-advanced

- Phase 2 combination trial in two metastatic breast cancer (MBC) populations initiated for Merus’ most advanced bispecific antibody candidate, MCLA-128 - - Strategic collaboration announced with Simcere Pharmaceutical Group for multiple bispecific antibodies; expanded collaboration with Ono

Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands , April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the

UTRECHT, The Netherlands , March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), and the Vall d’Hebron Institute of Oncology (VHIO), a leading comprehensive cancer center of

UTRECHT, The Netherlands , March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ono Pharmaceutical Co. , LTD. ( Osaka, Japan , ‘Ono’) has exercised its option

Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® Technology for Efficient Generation of Biclonics® Candidates UTRECHT, The Netherlands , March 13, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific

UTRECHT, The Netherlands , March 06, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview

UTRECHT, The Netherlands , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that it has agreed to sell 3.1 million shares of its common shares to Biotechnology

UTRECHT, The Netherlands , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company’s management will participate at four upcoming investor conferences

Combination trial to evaluate MCLA-128 in HER2-positive and hormone receptor-positive/HER2-low metastatic breast cancer patients UTRECHT, the Netherlands , Jan. 26, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody

UTRECHT, Netherlands and NANJING , China , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus has agreed to grant Simcere an exclusive license to develop and commercialize in China three bispecific antibodies utilizing Merus’

- IND submitted to U.S. FDA for MCLA-117 in AML - - First CTA approval for MCLA-158 received in European country -  UTRECHT, The Netherlands , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics

UTRECHT, The Netherlands , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 36 th

UTRECHT, The Netherlands , Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced that the United States Court of Appeals for the Federal Circuit denied Regeneron

UTRECHT, The Netherlands , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced financial results for the third quarter ended September 30, 2017 and provided a

UTRECHT, The Netherlands , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday,

UTRECHT, The Netherlands , Oct. 10, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will be participating in the 2017 BIO Investor

UTRECHT, The Netherlands , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Merus (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, announced today that it has added to its deep intellectual property portfolio two new U.S.

UTRECHT, The Netherlands , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced financial results for the second quarter ended June 30, 2017 and provided a

UTRECHT, The Netherlands , Aug. 30, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will participate at two upcoming

UTRECHT, The Netherlands , Aug. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview

UTRECHT, The Netherlands , July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the trial court’s

Balance sheet strengthened with $120 million upfront payment and an $80 million share purchase from Incyte Corporation for global strategic research collaboration to discover and develop bispecific antibodies Based on single agent activity in the MCLA-128 Phase 1/2 clinical trial, Phase 2

Conference call and webcast scheduled on 4:30pm ET UTRECHT, The Netherlands , July 06, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the company will provide an

Utrecht, The Netherlands— June 2017 —Ton Logtenberg, Founder and Chief Executive Officer of Merus N.V. will participate in a BioPharma Dealmakers webcast, sponsored in part by Merus N.V., featuring three other companies innovating cancer immunotherapy.

UTRECHT, The Netherlands , June 01, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the

Results to be presented at the 2017 American Society of Clinical Oncology Annual Meeting Phase 2 clinical trial to be initiated in second half of 2017 exploring two metastatic breast cancer populations: HER2-positive patients and hormone receptor-positive/HER2-low patients UTRECHT, The Netherlands

UTRECHT, The Netherlands , May 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 24 ,

In a release issued April 28, 2017 by Merus N.V. (Nasdaq:MRUS) with the same headline, an error was made such that the figures for the three months ended December 31, 2016 in the “Consolidated Statement of Profit or Loss and Comprehensive Loss” table were incorrect.

UTRECHT, The Netherlands , April 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the fourth quarter and full year ended December 31, 2016 and provided a

UTRECHT, The Netherlands , April 20, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that data from a Phase 1/2 study of MCLA-128 for the treatment of metastatic breast cancer will be

Award Recognizes Company’s Substantial Transformation and Breakthroughs Over Past 12 Months UTRECHT, The Netherlands , March 16, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that

UTRECHT, The Netherlands , Feb. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the Cowen

UTRECHT, The Netherlands , Feb. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will participate at the Leerink Partners 6 th

UTRECHT, The Netherlands , Jan. 23, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of its global strategic research collaboration with Incyte Corporation (NASDAQ:INCY)

UTRECHT, The Netherlands , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and the Institute for Research in Biomedicine (IRB) Barcelona , a research center devoted to understanding

Collaboration designed to leverage Merus ’ Biclonics ® bispecific antibody technology to expand Incyte ’ s discovery capabilities and large-molecule portfolio Incyte to make up-front payment of $120 million and purchase $80 million of Merus common shares; Merus eligible to receive potential

European Patent Office Dismisses Arguments by Regeneron Favorable Rulings Further Strengthen IP Estate in Europe and Japan through 2029 UTRECHT, The Netherlands , Nov. 15, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific

UTRECHT, The Netherlands , Nov. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday,

UTRECHT, The Netherlands and EDINBURGH, UK , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that it has been awarded  a €1.5 million EUREKA Eurostars grant (“iMOD-ReACT”)

UTRECHT, The Netherlands , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the third quarter ended September 30, 2016 and provided a review of recent

Former CFO Shelley Margetson Elevated to Chief Operating Officer UTRECHT, The Netherlands , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of John Crowley as

UTRECHT, The Netherlands , Oct. 26, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of L. Andres Sirulnik , MD, PhD, to the position of Chief Medical Officer, where he

UTRECHT, The Netherlands , Oct. 19, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company received an undisclosed milestone payment from Ono Pharmaceutical Co., LTD.

UTRECHT, The Netherlands , Aug. 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences: Ton Logtenberg,

UTRECHT, The Netherlands , Aug. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday,

UTRECHT, The Netherlands , Aug. 08, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2016 and provided a review of recent

Raises $53.3 Million in Successful Initial Public Offering Doses First Patient in Phase 1/2 Study of MCLA-117 in Patients with AML UTRECHT, The Netherlands, July 12, 2016 (GLOBE NEWSWIRE) -- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics,

Bispecific Cancer Antibody Pipeline Optimized by GlymaxX® Manufacturing Technology BERLIN & UTRECHT, The Netherlands , June  01, 2016  (GLOBE NEWSWIRE) -- ProBioGen AG and Merus N.V. (Nasdaq:MRUS) today jointly announced that Merus has signed a commercial multi-product license

UTRECHT, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. ("Merus") ( MRUS ), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of a partial exercise of the over-allotment option by the underwriters of its

UTRECHT, the Netherlands , May 24, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (“Merus”) (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share.  The shares began trading on The NASDAQ Global Market under

UTRECHT, the Netherlands , May 18, 2016 (GLOBE NEWSWIRE) -- Merus B.V. (“Merus”) today announced the pricing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share, before underwriting discounts and commissions.

UTRECHT, The Netherlands (GLOBE NEWSWIRE) — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the first patient has been dosed in the Company's Phase 1/2 clinic al trial evaluating MCLA-117 as a potential treatment of

MCLA-128 Shows Favorable Safety Profile and Early Signs of Anti-Tumor Activity in Patients with Advanced Solid Tumors UTRECHT, The Netherlands, April 15, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics),

Utrecht, The Netherlands, March 9, 2016 - Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the United States Patent and Trademark Office (USPTO) has issued three patents related to the generation of bispecific

Utrecht, The Netherlands and Villejuif, France, January 4, 2016 — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and Institut Gustave Roussy, a leading Comprehensive Cancer Centre in Europe, today announced entry into a strategic

Novartis Oncology ’ s Former Global Head of Business Development and Licensing Joins Immuno-oncology Biotech Company Utrecht, The Netherlands, December 16, 2015 — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the

Court Further Rules That Regeneron Engaged in Affirmative Egregious Misconduct UTRECHT, The Netherlands, Nov. 3, 2015 (GLOBE NEWSWIRE) — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the U.S.

Utrecht, The Netherlands., August 26, 2015  – Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has entered into an agreement with investors for the sale of up to € 72.8 million ($80.5 million) of Series C

• Court ruling further strengthens Merus’ freedom to operate in using transgenic mice for therapeutic human antibodies Utrecht, The Netherlands, August 10, 2015 — Merus, a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that it won

Utrecht, The Netherlands, June 1, 2015 — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that Mark Iwicki has been appointed as President of its Supervisory Board. “We welcome Mark as an instrumental addition to our

Utrecht, The Netherlands, May 20, 2015 — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, and Selexis SA, a serial innovation company with proven technologies for biologics drug discovery and Research Cell Bank (RCB) development, today

– Successful product lead identification underscores the strength of Merus’ platform in delivering human, full-length IgG bispecific antibodies – Utrecht, The Netherlands, 8th April 2015 – Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics, announced today that it has

– First patient dosed in trial with potent bispecific antibody overcoming resistance to HER2-targeted therapies – Utrecht, The Netherlands, February 4, 2015 — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced the initiation

Posted on 5 January, 2015 Merus B.V., a leader in developing best-in-class antibody therapeutics to treat cancer patients, today announced a series of pivotal events in its litigation with Regeneron Pharmaceuticals Inc. Previously, Regeneron sued Merus accusing it of infringing U.S. Patent No.

Posted on 23 December, 2014 33rd Annual J.P. Morgan Healthcare Conference, San Francisco January 12-15, 2015

Posted on 3 November, 2014   Merus to present at the annual Protein & Antibody Engineering Summit (PEGS), Lisbon on November 4, 2014.

Posted on 18 September, 2014 In 2012, Regeneron was granted a European patent entitled “Methods of Modifying Eukaryotic Cells”. The patent is part of Regeneron’s IP portfolio around its VelocImmune® mouse for therapeutic human antibodies. Merus filed an opposition against this patent in June 2013,

Posted on 4 March, 2014 Under the terms of the agreement, ProBioGen is granting Merus the non-exclusive right to use the GlymaxX® technology to enhance the ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of one of its lead products, a bispecific anti-cancer antibody.

Posted on 23 October, 2013 Using standard industry processes, MeMo®-derived common light chain antibodies can be manufactured in clonal cell lines to efficiently obtain full-length IgG human bispecific antibodies (branded as Biclonics™) for therapy.

Posted on 1 July, 2013 MCLA-117 is a human, full-length IgG bispecific antibody, which activates the patient’s own immune system by simultaneously binding to the CLEC12A molecule expressed by AML tumor cells and the CD3 molecule expressed by T cells.

Posted on 17 June, 2013 The compound is being developed for the treatment of acute myeloid leukemia (AML), a disease with very poor long-term prognosis.   MCLA-117 activates the patient’s own immune system by simultaneously binding to the CLEC12A molecule expressed by AML tumor cells and the

Posted on 10 March, 2013 Johnson & Johnson Development Corporation (JJDC) joined as a new investor along with existing investors Novartis Venture Fund, Pfizer Venture Investments, Bay City Capital, LSP (Life Sciences Partners), and Aglaia Oncology Fund.

Posted on 7 March, 2013 Under an agreement signed with R&D service provider FairJourney Biologics, Merus will strengthen its R&D resources for selecting the most promising common light chain antibodies generated by its MeMo® transgenic mouse.

Posted on 7 February, 2013 In 2010, Merus had entered into an option agreement with the Novartis Option Fund for an exclusive license to one of Merus’ oncology programs. The deal grants the Novartis Option Fund rights to a product candidate created by the Biclonics™ and Oligoclonics™ technologies

Posted on 14 January, 2013 “This agreement builds on a successful pilot study to test the suitability of the OcellO platform for screening Merus’ therapeutic bispecific antibodies,” said Dr. Leo Price, Chief Scientific Officer at OcellO. “It aims to establish a long-term relationship between OcellO

Posted on 11 December, 2012 Setareh van Driel Shamsili has more than 22 years of experience in general medicine, internal medicine and medical oncology. For the past 13 years, she has focused on both translational and clinical cancer research. She has more than eight years of experience in the

Posted on 8 October, 2012 The MeMo® mouse creates human antibody diversity using a large repertoire of human heavy chains paired with a common human light chain.   “Over the last year, we have immunized MeMo® mice with half a dozen antigens and analyzed the immune response,” said Mark Throsby,

Posted on 20 June, 2012 Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that it has been granted the first European patent covering its Oligoclonics® technology from a patent family that already comprises 4 issued US patents.

Posted on 15 June, 2012 Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that Jason Avery has been appointed as Chief Business Officer. With a professional background as Head of Business Development at Affitech A/S and Chief Business

Posted on 27 September, 2011 Merus announced today that it has completed the construction of a single-light chain transgenic mouse for the generation of therapeutic human monoclonal antibodies.  MeMo™ provides rapid access to large collections of high affinity antibodies for direct functional

Posted on 16 May, 2011 Utrecht, The Netherlands and Zurich, Switzerland, May 16 2011 – Merus BV and ChromaCon AG announced today the award of a EUREKA Eurostars grant with a total budget of €1.8 million to discover and develop bispecific antibodies for treatment of metastatic breast cancer.

Posted on 19 September, 2010 Dutch biopharmaceutical company Merus announced today that Dr. Wolfgang (Wolf) Berthold has joined its Supervisory Board.   “We are delighted to appoint Wolf Berthold in Merus’s Supervisory Board. He brings with him a wealth of industry and product development

Posted on 2 June, 2010 Merus BV today announced the April 16, 2010 online publication of data by J. de Kruif et. al., in the  ‘Early View’ section of the journal Biotechnology and Bioengineering that demonstrate for the first time the feasibility of producing mixtures of human monoclonal

Utrecht, The Netherlands, January 29, 2010 – Merus, a biopharmaceutical company located in Utrecht, The Netherlands, announced today that it has closed a €21.7 million ($30.7 million) Series B financing round led by new investors the Novartis Option Fund, Pfizer Inc.

Posted on 15 December, 2009 Merus BV, a biopharmaceutical company focused on the discovery and development of mixtures of human therapeutic antibodies, today announced that it has received a grant worth € 0.67 million for the development of an antibody combination therapy for chronic inflammatory